Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Synthovial Seven

This article was originally published in The Tan Sheet

Executive Summary

Supplement marketer Hyalogic receives a May 5 FDA warning letter following an inspection last winter. Investigators collected labeling for Synthovial Seven stating "Hyaluronic acid (HA) has been proven by numerous medical studies to alleviate pain and suffering from arthritis of the knee and other joints" and "Patent approved for...arthritis and fibromyalgia." Although the product is labeled a dietary supplement, the claims render the product a drug, FDA states. Moreover, claims such as "more cushioning and lubricating properties for the joints" are not supported by scientific evidence. Edwardsville, Kansas-based firm says they are communicating with the agency and have hired a consultant to be sure they remain FDA compliant...
Advertisement
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS096866

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel